LUMIRADX LTD (LMDX) Stock Fundamental Analysis

NASDAQ:LMDX • KYG5709L1095

0.016 USD
-0.02 (-53.49%)
At close: Jan 8, 2024
0.0136 USD
0 (-15%)
After Hours: 1/8/2024, 8:17:43 PM
Fundamental Rating

1

LMDX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. LMDX may be in some trouble as it scores bad on both profitability and health. LMDX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year LMDX has reported negative net income.
  • LMDX had a negative operating cash flow in the past year.
LMDX Yearly Net Income VS EBIT VS OCF VS FCFLMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -100M -200M -300M -400M

1.2 Ratios

  • LMDX has a Return On Assets of -99.18%. This is amonst the worse of the industry: LMDX underperforms 82.91% of its industry peers.
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROIC N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMDX Yearly ROA, ROE, ROICLMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 100 -100 200 300 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LMDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMDX Yearly Profit, Operating, Gross MarginsLMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -200 -400

1

2. Health

2.1 Basic Checks

  • LMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LMDX has less shares outstanding than it did 1 year ago.
  • LMDX has a worse debt/assets ratio than last year.
LMDX Yearly Shares OutstandingLMDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M
LMDX Yearly Total Debt VS Total AssetsLMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • LMDX has an Altman-Z score of -6.66. This is a bad value and indicates that LMDX is not financially healthy and even has some risk of bankruptcy.
  • LMDX has a worse Altman-Z score (-6.66) than 72.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACC4.03%
LMDX Yearly LT Debt VS Equity VS FCFLMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

  • LMDX has a Current Ratio of 1.97. This is a normal value and indicates that LMDX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.97, LMDX is not doing good in the industry: 74.37% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.01 indicates that LMDX should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.01, LMDX is doing worse than 82.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.01
LMDX Yearly Current Assets VS Current LiabilitesLMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 100M 200M 300M 400M

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.80% over the past year.
  • Looking at the last year, LMDX shows a very negative growth in Revenue. The Revenue has decreased by -68.26% in the last year.
  • The Revenue has been growing by 122.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%

3.2 Future

  • Based on estimates for the next years, LMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.53% on average per year.
  • LMDX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.56% yearly.
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LMDX Yearly Revenue VS EstimatesLMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
LMDX Yearly EPS VS EstimatesLMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

  • LMDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LMDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMDX Price Earnings VS Forward Price EarningsLMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMDX Per share dataLMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LMDX's earnings are expected to grow with 22.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.53%

0

5. Dividend

5.1 Amount

  • No dividends for LMDX!.
Industry RankSector Rank
Dividend Yield N/A

LUMIRADX LTD

NASDAQ:LMDX (1/8/2024, 8:17:43 PM)

After market: 0.0136 0 (-15%)

0.016

-0.02 (-53.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)03-19
Inst Owners0.11%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.63M
Revenue(TTM)126.50M
Net Income(TTM)-338.00M
Analysts82.5
Price Target1.22 (7525%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.35%
Min EPS beat(2)-12.04%
Max EPS beat(2)5.34%
EPS beat(4)1
Avg EPS beat(4)-35.59%
Min EPS beat(4)-77.22%
Max EPS beat(4)5.34%
EPS beat(8)2
Avg EPS beat(8)-68.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.56%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)11.29%
Revenue beat(4)2
Avg Revenue beat(4)3.57%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)11.29%
Revenue beat(8)5
Avg Revenue beat(8)10.8%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)5.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.77
BVpS-1.31
TBVpS-1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.03%
Cap/Sales 8.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.01
Altman-Z -6.66
F-Score1
WACC4.03%
ROIC/WACCN/A
Cap/Depr(3y)359.47%
Cap/Depr(5y)273.18%
Cap/Sales(3y)27.1%
Cap/Sales(5y)32.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%
EBIT growth 1Y-149.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.43%
EBIT Next 3Y23.29%
EBIT Next 5YN/A
FCF growth 1Y22.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.46%
OCF growth 3YN/A
OCF growth 5YN/A

LUMIRADX LTD / LMDX FAQ

Can you provide the ChartMill fundamental rating for LUMIRADX LTD?

ChartMill assigns a fundamental rating of 1 / 10 to LMDX.


What is the valuation status of LUMIRADX LTD (LMDX) stock?

ChartMill assigns a valuation rating of 1 / 10 to LUMIRADX LTD (LMDX). This can be considered as Overvalued.


How profitable is LUMIRADX LTD (LMDX) stock?

LUMIRADX LTD (LMDX) has a profitability rating of 0 / 10.


Can you provide the financial health for LMDX stock?

The financial health rating of LUMIRADX LTD (LMDX) is 1 / 10.


Can you provide the expected EPS growth for LMDX stock?

The Earnings per Share (EPS) of LUMIRADX LTD (LMDX) is expected to grow by 70.33% in the next year.